Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing...
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing...
Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study...
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the...
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy...
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared...
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared...
Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use...
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of...
BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the...
Weekly subcutaneous doses of pemvidutide resulted in robust reductions in cardio-inflammatory, hepato-inflammatory and atherosclerotic lipids Findings support the potential benefit...
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage DeterminationCANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE)...
NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The global electronic health records...
WASHINGTON--(BUSINESS WIRE)--#CALiD--Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food...
Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company...
BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) ("CASI" or the "Company"), a Cayman incorporated...
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed...
CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment...
RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCEParsortix-based HER2 kit being developed...
Marlborough, Massachusetts--(Newsfile Corp. - November 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company exploring new...
PHILADELPHIA, Nov. 14, 2024 /PRNewswire/ -- Health Union, the leading digital health company building online communities that empower people to live...